Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33

Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33...

Descripción completa

Detalles Bibliográficos
Autores principales: Azoitei, Ninel, Hoffmann, Christopher M., Ellegast, Jana M., Ball, Claudia R., Obermayer, Kerstin, Gößele, Ulrike, Koch, Britta, Faber, Katrin, Genze, Felicitas, Schrader, Mark, Kestler, Hans A., Döhner, Hartmut, Chiosis, Gabriela, Glimm, Hanno, Fröhling, Stefan, Scholl, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328372/
https://www.ncbi.nlm.nih.gov/pubmed/22451720
http://dx.doi.org/10.1084/jem.20111910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328372/
https://www.ncbi.nlm.nih.gov/pubmed/22451720
http://dx.doi.org/10.1084/jem.20111910

Ejemplares similares